Abstract: A multiple emulsion to administer at least one water-soluble or liposoluble active ingredient in the form of a water/oil/water emulsion comprising a dispersed phase of a water/oil type and an aqueous dispersion medium which is a gelled aqueous phase useful as cosmetic compositions for external skin application.

Abstract: Cosmetic or dermatological compositions for skin care, characterized in that they contain ribosomes extracted from vegetable or animal cells or from the cells of micro-organisms.

Abstract: A cosmetic or dermatological composition containing a skin enhancing agent consisting essentially of a) at least one .alpha.-hydroxy acid, b) salicylic acid or esters thereof and c) at least one retinoid in a skin enhancing method.

Abstract: The invention provides compounds of formula I ##STR1## and pharmaceutically acceptable salts thereof; wherein R.sub.50 is hydrogen or C.sub.1-4 alkyl, A.sub.51 is oxygen, sulphur or a group of the formula --NR.sub.52 -- wherein R.sub.52 is hydrogen or C.sub.1-4 alkyl; A.sub.50 comprises i) a mono or bicyclic aromatic ring optionally containing one or more nitrogen, oxygen or sulphur atoms, ii) a cycloalkendiyl group, or iii) an acyclic bridging group having a chain of one, two or three atoms between the cyclobutenedione group and X.sub.50, said chain being a chain of one or two carbon atoms or a chain of one carbon atom and one or more nitrogen, oxygen or sulphur atoms or iv) a bond; X.sub.50 is either a bond or a spacer group providing a chain between A.sub.50 and B.sub.50 of one or two atoms length; B.sub.

Abstract: Compounds of formula I ##STR1## and pharmaceutically acceptable salts thereof in which m is an integer from 1 to 3; n is an integer from 2 to 6; R.sub.1 is phenyl optionally substituted by one or more substituents selected from halo, hydroxy, alkoxy, alkanoyl, alkyl, halogenated alkyl, alkylthio, alkylsulphinyl, alkylsulphonyl, cyano, nitro, optionally substituted amino, optionally substituted sulphamoyl, optionally substituted carbamoyl or phenyl, or R.sub.1 is naphthyl;R.sub.2 is H, alkyl or phenyl;R.sub.3 is H, alkyl, alkenyl or alkoxyalkyl;R.sub.4 is H or hydroxy; andR.sub.5 is H or together with R.sub.4 represents a bond;have utility in the treatment of obesity and affective disorders such as depression and anxiety.

Abstract: The preparation of metal oxide particles having a dye lake precipitated onto their surface in a dye lake:metal oxide ratio of between 10:90 and 80:20 and the use of such particles in cosmetic and toiletry formulations are described.

Abstract: Anti-microbial compositions are described which contain iodide and thiocyanate anions, an oxidoreductase enzyme, namely glucose oxidase, and its corresponding oxidisable substrate, D-glucose. Such compositions may advantageously further comprise a peroxidase such as lactoperoxidase. The compositions have excellent anti-microbial properties effective against bacteria yeasts and moulds. The compositions may be provided in concentrated substantially non-reacting forms such as dry powders and non-aqueous solutions which may be diluted to provide compositions with broad spectrum anti-microbial activity. Compositions may be used as preservatives or as active agents providing potent anti-microbial activity of use in oral hygiene, deodorant and anti-dandruff products.

Abstract: A process for the production of a product which is enriched in a desired enantiomer of a phenylpropionic acid selected from ibuprofen and flurbiprofen, or their pharmaceutically acceptable salts, which comprises a resolution stage, a recrystallization stage, an optional liberation stage, and an optional salt preparation stage. A substantially racemic mixture of the phenylpropionic acid is contacted with an enantiomer of .alpha.-methylbenzylamine, in specific ratios, to produce the enantiomerically enriched product.

Abstract: Compounds of formula I ##STR1## in which n=0, 1 or 2;R.sub.1, R.sub.2, R.sub.6 and R.sub.7 independently represent H or alkyl (optionally substituted by one or more halo);R.sub.3 and R.sub.4 independently represent H or alkyl or together represent a group of formula .dbd.NR.sub.12 where R.sub.12 represents H, hydroxy, alkyl, phenyl or alkoxy; each alkyl, phenyl and alkoxy being optionally substituted with one or more halo;R.sub.5 represents: (a) H, (b) alkyl, (c) a group of formula --COR.sub.13 in which R.sub.13 is H, alkyl or phenyl, when R.sub.3 and R.sub.4 represent H or alkyl (optionally substituted with one or more halo), or (d) a group of formula --S(O).sub.p R.sub.14 in which p=1 or 2 and R.sub.14 is alkyl or phenyl, when R.sub.3 and R.sub.4 represent H or alkyl (optionally substituted with one or more halo); each alkyl and phenyl optionally substituted with one or more halo;and R.sub.8 to R.sub.

Abstract: This invention relates to compounds of formula I and pharmaceutically acceptable salts thereof ##STR1## in which R.sub.1, R.sub.2 and R.sub.3 independently represent hydrogen, halo, alkyl, alkoxy, phenoxy, phenyl, alkoxycarbonyl, --NR.sub.13 R.sub.14, halogenated alkoxy, halogenated alkyl, benzyloxy, hydroxy, hydroxyalkyl, (C.sub.2-6 alkoxycarbonyl)vinyl, --S(O).sub.n R.sub.7, carbamoylalkyl, alkoxycarbonylalkyl, --CONR.sub.11 R.sub.12, or R.sub.1 and R.sub.2 together with the phenyl ring represent a naphthyl group; R.sub.4 and R.sub.5 independently represent hydrogen, alkyl, phenyl or together with the carbon atom represent C.sub.3-6 cycloalkyl; R.sub.6 represents hydrogen, alkyl or .omega.-hydroxy alkyl; A represents C.sub.2-9 alkylene; R.sub.8 represents hydrogen, alkyl, halo, alkoxy, hydroxyalkyl, benzyl or phenyl; R.sub.9 and R.sub.10 independently represent hydrogen, alkyl, halo, alkoxy, phenyl, hydroxyalkyl, alkoxycarbonyl, nitro, --NR.sub.30 R.sub.

Abstract: Tetrahydroisoquinoline compounds of formula I ##STR1## and pharmaceutically acceptable salts and lipophilic ester thereof have utility as analgesics and in the treatment of psychoses, Parinson's disease, Lesch-Nyan syndrome, attention deficit disorder or cognitive impairment or in the relief of drug dependence or tardive dyskinesia.

Abstract: A process for the preparation of a pharmaceutical composition in the form of agglomerates comprising 70-97% by weight of 2-(4-isobutylphenyl)propionic acid or a pharmaceutically acceptable salt thereof and 3-30% by weight of a starch component, said process comprising the steps of a) forming an emulsion comprising 1) 70-97% by weight of 2-(4-isobutylphenyl)propionic acid or a salt thereof 2) a solvent system 3) 3-30% by weight of the starch component 4) water and optionally 5) a surfactant b) crystallising to produce a suspension comprising crystals of 2-(4-isobutylphenyl)propionic acid or the salt thereof in intimate contact with the starch component c) agitating said suspension to form agglomerates comprising an evenly distributed mixture of 2-(4-isobutylphenyl)propionic acid or a salt thereof and the starch component d) collecting said agglomerates and optionally e) drying said agglomerates. Pharmaceutical formulations comprising 90-99.98% by weight of such a composition together with 0.

Abstract: A pharmaceutical composition comprising purified chymopapain and a reducing agent is presented. The purified chymopapain in this composition has a specific activity against 1 mM of N-.alpha.-benzoyl-DL-arginine p-nitroanilide at 40.degree. C. and pH 6.8 of between 3,000 and 4,500 units per mg, and contains less than 0.2% each of papaya proteinase III (PPIII), papain, and papaya proteinase IV (PPIV).

Abstract: This invention relates to compounds of formula I and pharmaceutically acceptable salts thereof ##STR1## in which R.sub.1 represents hydrogen, alkyl, hydroxy, carboxyalkenyl, alkoxycarbonyalkenyl, hydroxyalkyl, carboxyalkyl, alkoxycarbonylalkyl, alkoxy, halogenated alkyl, carboxy alkoxycarbonyl or alkanoylamino; R.sub.2 represents hydrogen, halo, alkoxy, hydroxy, alkanoyloxy, or phenoxy; R.sub.3 represents hydrogen or alkyl; R.sub.4 represents hydrogen, halo, alkoxycarbonyl, a benzyloxycarbonyl, alkanoyl, benzoyl, carbamoyl, alkyl, carboxy, hydroxyalkyl or alkylthio; R.sub.5 represents hydrogen or alkyl; R.sub.6 represents hydrogen, alkyl [optionally substituted by one or more of the following: hydroxy, halo or an amino group of formula --NR.sub.12 R.sub.13 ], a C.sub.3-12 alicyclic hydrocarbon group, phenyl, (cycloalkyl)alkyl or benzyl; R.sub.7 represents hydrogen, halo, trifluoromethyl, trifluoromethoxy, alkyl, carboxy, or alkoxy; R.sub.

Abstract: The invention relates to titanium dioxide sunscreen compositions containing 0.025 to 30% by weight of phosphate anions. Phosphate anions, preferably in the form of salts, have been found to prevent or reduce the rate of discolouration of titanium dioxide-containing sunscreen compositions caused by light catalysed reduction of titanium (IV) to titanium (III). Discolouration caused by the presence of parahydroxybenzoic acid esters or para-aminobenzoic acids, esters or derivatives thereof in such compositions has also been found to be reduced by the incorporation of phosphate salt.Titanium dioxide particles having a mean primary particle size of less than 100 nm, each of the particles being substantially coated with phosphate anions are also described for use in sunscreen compositions.

Abstract: N,N-dimethyl-1-[ 1-(4-chlorophenyl)cyclobutyl] -3-methylbutylamine hydrochloride is used in the treatment of obesity in humans.

Abstract: A sustained release pharmaceutical formulation comprising xanthan gum, a pharmaceutically active ingredient for example, ibuprofen or flurbiprofen, and other optional excipients.

Abstract: A method of purifying chymopapain by active site directed affinity chromatography using inhibitory dipeptides as affinity ligands is presented. The inhibitory dipeptides have C-terminal aldehyde derivatives of phenylalanine selected from the group consisting of the semicarbazone, the methoxyimine and the oxime. The purified chymopapain has a specific activity against BAPNA (1 mM) at 40.degree. C. and pH 6.8 of between 3000 and 4500 units per mg and contains less than 0.2% each of papaya proteinase III (PPIII), papain and papaya proteinase IV (PPIV). The use of purified chymopapain in pharmaceutical compositions for the treatment of damaged mammalian spinal discs is also disclosed.